Cargando…

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

Treatment with Daratumumab (Dara), a monoclonal anti-CD38 antibody of IgG1 subtype, is effective in patients with multiple myeloma (MM). However, Dara also impairs the cellular immunity, which in turn may lead to higher susceptibility to infections. The exact link between immune impairment and infec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nahi, Hareth, Chrobok, Michael, Gran, Charlotte, Lund, Johan, Gruber, Astrid, Gahrton, Gösta, Ljungman, Per, Wagner, Arnika Kathleen, Alici, Evren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374018/ https://www.ncbi.nlm.nih.gov/pubmed/30759167 http://dx.doi.org/10.1371/journal.pone.0211927

Ejemplares similares

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
por: Gran, Charlotte, et al.
Publicado: (2020)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
por: Chrobok, Michael, et al.
Publicado: (2019)

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
por: Susek, Katharina H., et al.
Publicado: (2022)

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
por: Gahrton, Gösta
Publicado: (2023)

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
por: Jakobsen Falk, Ingrid, et al.
Publicado: (2017)

The Effect of Mesenchymal Stromal Cells Derived From Endometriotic Lesions on Natural Killer Cell Function
por: Abomaray, Fawaz, et al.
Publicado: (2021)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
por: Iida, Shinsuke, et al.
Publicado: (2021)

P1443: AUTOLOGOUS NK CELLS AS CONSOLIDATION AFTER FRONT-LINE STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A LONG-TERM FOLLOW-UP
por: Lund, J., et al.
Publicado: (2022)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
por: Facon, Thierry, et al.
Publicado: (2022)

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
por: Gahrton, Gösta, et al.
Publicado: (2020)

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
por: San-Miguel, Jesus, et al.
Publicado: (2020)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2023)

Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
por: Lejeune, Margaux, et al.
Publicado: (2021)

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
por: Usmani, Saad Z., et al.
Publicado: (2022)

Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
por: Kalis, Joseph A.
Publicado: (2017)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
por: Zajec, Marina, et al.
Publicado: (2020)

Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
por: Agrawal, Soma, et al.
Publicado: (2020)

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018)

New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim, Cian, et al.
Publicado: (2017)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab
por: Meng, Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ghrlvb8mkphd97ihlvr579v718